

# Pure total flavonoids from citrus attenuate non-alcoholic fatty liver disease in mice via the gut microbiota

**Beihui He**

Zhejiang Chinese Medical University

**Jianping Jiang**

Zhejiang Chinese Medical University

**Zheng Shi**

Zhejiang Chinese Medical University

**Dawei Cui**

Zhejiang University School of Medicine First Affiliated Hospital

**Sumei Xu**

Zhejiang Chinese Medical University

**Maoxiang Yan**

Zhejiang Chinese Medical University

**Shuo Zhang**

Zhejiang Chinese Medical University

**Zhiyun Chen** (✉ [zhiyunchen63@163.com](mailto:zhiyunchen63@163.com))

Zhejiang Chinese Medical University

---

## Research article

**Keywords:** Pure total flavonoids from citrus, NAFLD, Gut microbiota, HFD diet, 16S rDNA

**Posted Date:** February 29th, 2020

**DOI:** <https://doi.org/10.21203/rs.3.rs-15520/v1>

**License:** © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

# Abstract

**Background** An increasing number of studies suggest that gut microbiota composition and structure contribute to the pathophysiology of non-alcoholic fatty liver disease (NAFLD), and the gut microbiota has been proposed as a new target in the treatment of diet-induced NAFLD. In this study, we aimed to investigate the effects of pure total flavonoids from citrus (PTFC) on NAFLD and gut microbiota dysbiosis in high-fat diet (HFD)-fed mice and to further investigate whether the attenuation of NAFLD is related to the modulation of the gut microbiota. **Results** PTFC intervention could significantly attenuate symptoms in mice with HFD-induced NAFLD. Based on the results of 16S rDNA sequencing, PTFC treatment could increase the phylogenetic diversity of the HFD-induced microbiota. PTFC intervention could significantly restore the HFD-induced increases in the relative abundances of Bacteroidaceae and Christensenellaceae. **Conclusion** Our results suggested that PTFC could serve as a novel candidate for the prevention of NAFLD by modulating the gut microbiota.

## Background

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide, affecting up to 25% of adults and children [1–3]. The spectrum of NAFLD ranges from simple nonalcoholic fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH), which can progress to liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) [4, 5]. NAFLD is strongly associated with obesity and obesity-related metabolic disorders [6, 7]. NAFLD pathogenesis was initially explained by the two-hits hypothesis, but this theory failed to explain various NAFLD-related molecular changes, resulting in the adoption of the multiple-hits hypothesis, which takes into account the complex and multifactorial aspects of the disease [8, 9].

A large amount of evidence has revealed that the gut microbiota plays vital roles in the regulation of NAFLD by producing bacterial metabolites such as short-chain fatty acids, indole and its derivatives, secondary bile acids, and trimethylamine [10–12].

Pure total flavonoids from citrus (PTFC) were isolated and purified from dried and mature peel of Citrus Varieties (Changshan Huyou) in Changshan and Quzhou of Zhejiang province, China. PTFC is composed of naringin, neohesperidin and narirutin, the total content of flavonoids is over 76%. Naringin can reduce lipid synthesis, improve lipid deposition and reduce inflammatory cell infiltration in the liver of rats induced by high-fat diet [13–15]. The bioactive naringin is the main metabolite of naringin in human intestinal microbial environment, which indicates that the microbiota play an important role in regulating the pharmacological action of naringin [16]. Our previous study showed that PTFC controlled the progression of NAFLD by regulating the TLR/CCL and VEGF-C signalling pathways [17–18].

In the present study, we examined whether PTFC could attenuate features of HFD-induced NAFLD in mice, which might be related to the modulation of the gut microbiota.

# Results

## PTFC ameliorates hepatic steatosis and fibrosis in HFD-fed mice

In our previous study[16], we reported that compared with the ND group, the liver tissues of mice in the HFD group showed obvious steatosis, inflammatory cell infiltration, and focal necrosis. Moreover, fibrous tissue deposition around the perisinusoidal and liver cells also occurred, and the NAFLD activity score (NAS) increased significantly. Compared with the HFD group, the HFD + PTFC group showed a decrease in hepatic steatosis, inflammatory cell infiltration, and degree of fibrosis as well as NAS.

## Overall structural modulation of the gut microbiota after PTFC treatment

16S rDNA sequencing analysis was used to investigate the structural changes in the gut microbiota in mice that received PTFC treatment. In total, 644541 useable reads were obtained from 15 samples, and 678 OTUs were collected. Similar to the previous findings, the diet was found to be a key factor in changing phylogenetic diversity. In this work, significant decreases in Chao1 and ACE, indicating lower microbiota community diversity, were found in the HFD and PTFC groups ( $P < 0.01$ , Fig.1A-C). The rank-abundance curve, rarefaction curve, sample Shannon curves and species accumulation curves show that the amount of sequencing data is reasonable (Fig. 1D-G).

## Lefse analysis

Different colours represent different groups. For example, the red node in the branch represents the species with a significantly higher abundance in the red group, the green node represents the species with a significantly higher abundance in the green group, and the yellow node represents the species without a significant abundance difference between groups. The node diameter is directly proportional to the relative abundance; the nodes in each layer represent phyla/classes/orders/families/genera/species, in that order; the annotation of each species represents phyla/class/order/family/genus/species, in that order. The annotation of the phylum level is displayed on the outermost ring, while the annotation information of the other levels is displayed in Fig.2A-B. Bacteroidaceae and Rikenellaceae were increased in the PTFC group at the family level ( $P < 0.05$ ). Porphyromonadaceae and Enterococcaceae were increased in the HFD group at the family level ( $P < 0.05$ ).

## Venn diagram

From the Venn diagram, we can see the unique OTUs and the common OTUs of each group, indicating the unique species information of each group more directly. Different numbers of OTUs were detected in each group, i.e., 638 in the normal group, 478 in the HFD group, and 458 in the PTFC group (Fig. 2C). Among all OTUs, 385 were shared by all groups. Additionally, each group had unique OTUs, including 132 in the normal group, 4 in the HFD group, and 21 in the PTFC group.

## Analysis of the whole intestinal microbiota composition

At the family level, compared with the normal group, the relative abundance of Christensenellaceae and Erysipelotrichaceae was decreased in the HFD group. After PTFC treatment, the relative abundance of Christensenellaceae and Erysipelotrichaceae were significantly increased ( $P < 0.01$ ). The relative abundance of Porphyromonadaceae and Streptococcaceae increased in the HFD group. After PTFC treatment, the relative abundance of Porphyromonadaceae and Streptococcaceae were significantly decreased ( $P < 0.01$ ,  $P < 0.05$ ) (Fig. 3A-D).

At the genus level, compared with the normal group, the relative abundance of Allobaculum was decreased in the HFD group. After PTFC treatment, the relative abundance of Allobaculum was significantly increased ( $P < 0.05$ ). The relative abundance of Eubacterium was increased in the HFD group. After PTFC treatment, the relative abundance of Eubacterium was significantly increased ( $P < 0.05$ ) (Fig. 3E and F).

At the family level, we found that the majority of the intestinal microbiota consisted of species from Porphyromonadaceae, Lachnospiraceae, Ruminococcaceae, Prevotellaceae, Desulfovibrionaceae, and Bacteroidaceae (Fig. 4A). Compared with the normal group, the abundance of Porphyromonadaceae was significantly increased in the HFD group. After treatment with PTFC, the abundance of Porphyromonadaceae in HFD-fed mice decreased ( $P < 0.01$ ) (Fig. 4C-E).

At the genus level, we found that the majority of the intestinal microbiota consisted of species from Clostridium\_IV, Bacteroides, Paraprevotella, Helicobacter, Elsenbergiella, and Parabacteroides (Fig. 4B). Compared with the normal group, the abundance of Paraprevotella was significantly decreased in the HFD group ( $P < 0.01$ ). After treatment with PTFC, the abundance of Bacteroides in the PTFC group increased ( $P < 0.05$ ), and Akkermansia was identified with an abundance of 4.4% (Fig. 4F-H).

### **PICRUSt Analysis and prediction of genomic functional changes among different groups**

Based on the 16S rDNA and reference sequence database, PICRUSt predicted the macrogenome functional composition of the flora. The accuracy of the method was 84-95%. In the PTFC group, 12 KEGG pathways were altered, including energy metabolism, amino acid metabolism, ethylbenzene degradation and peptidoglycan biosynthesis (Fig. 4I). Compared with the HFD group, other ion-coupled transporters were upregulated and beta-alanine metabolism, type I diabetes mellitus, ethylene degradation, energy metabolism, alanine, aspartate and glutamate metabolism were reduced (Fig. 4J). These significant pathway changes predicted that PTFC treatment could improve the gut microbiota structure of mice under the condition of HFD feeding, thus exerting a therapeutic effect against NASH in mice.

## **Discussion**

In our previous studies, we found that PTFC treatment could alleviate NAFLD by regulating the TLR/CCL inflammatory signalling pathways, the SIRT1/PGC-1 $\alpha$  pathways and Th17/treg balance [15, 17–

20]. However, the specific mechanism requires further study. In this study, we aimed to determine the preventive effects of PTFC on high-fat-diet (HFD)-induced NAFLD in mice and the underlying mechanism focusing on gut microbiota profile modulation.

In our study, we found that compared with the normal-diet group, HFD-induced NAFLD mice had differences at the phylum, class, and genus levels that resulted in gut microbiota dysbiosis. These changes were characterized by an increase in the Firmicutes/Bacteroidetes ratio and a dramatic decrease in the Christensenellaceae family compared to that in the normal diet group.

To study the underlying mechanism of PTFC in treating NASH, we investigated the positive effect of PTFC on the intestinal microbiota. In this study, as shown in Fig. 4, at the family level, compared with the normal group, the relative abundance of Christensenellaceae and Erysipelotrichaceae was decreased in the HFD group. After PTFC treatment, the relative abundance of Christensenellaceae and Erysipelotrichaceae were significantly increased. The relative abundance of Porphyromonadaceae and Streptococcaceae increased in the HFD group. After PTFC treatment, the relative abundance of Porphyromonadaceae and Streptococcaceae was significantly decreased. Christensenellaceae, a recently described family in the phylum Firmicutes, is emerging as an important player in human health [21]. Christensenellaceae is reported to be reduced in individuals with metabolic syndrome (MetS) compared to the level in healthy controls [22]. Stachyose improved the intestinal homeostasis of HFD-fed mice by improving the bacterial diversity with increases in the relative abundance of Christensenellaceae [23]. Erysipelotrichaceae was negatively correlated with body weight, while Porphyromonadaceae was positively correlated with body weight [24]. At the family level, Streptococcaceae was enriched in the NAFLD group [25, 26].

At the genus level, after treatment with PTFC, the abundance of the beneficial bacteria with protective effects in the body increased. The abundance of Bacteroides in the PTFC group increased, and Akkermansia increased at a ratio of 4.4%. Akkermansia has been inversely associated with obesity, diabetes, inflammation, and metabolic disorders [27, 28]. Due to its highly promising probiotic activities against obesity and diabetes, Akkermansia has drawn intense interest in the context of research and development in recent years [29].

To verify the metabolic function of the intestinal microbiota, the KEGG database was used to identify the relationship between metabolic function and host metabolites (Fig. 4I, J). In the PTFC group, 12 KEGG pathways were altered, including energy metabolism, amino acid metabolism, ethylene degradation and peptidoglycan biosynthesis (Fig. 4I). Compared with the HFD group, other ion-coupled transporters were upregulated, and beta-alanine metabolism, type I diabetes mellitus, ethylene degradation, energy metabolism, and alanine, aspartate and glutamate metabolisms were reduced (Fig. 4J). These significant pathway changes predicted that PTFC treatment could improve the gut microbiota structure of mice under the condition of HFD, thus exerting a therapeutic effect on NAFLD in mice.

## Conclusions

This study first analyzed the composition of gut microbiota in NAFLD mice induced by high-fat diet treated with PTFC. The results showed that PTFC increased the richness of the intestinal flora, adjusted the structure of the gut microbial community, and increased the relative abundances of the Bacteroidae, Christensenellaceae and Akkermansia. Therefore, our results indicate that the gut microbiota plays an important role in the progression of NAFLD, and PTFC can regulate this target to play an important therapeutic role.

## Methods

### Study Animals

All experimental procedures were approved by the Animal Ethics Committee of Zhejiang Chinese Medical University (ZSLL-2016-134) and the National Guidelines for Experimental Animal Welfare. A total of 18 C57BL/6J mice (6-8 weeks of age, male) were purchased from Shanghai Sippr-BK Laboratory Animal Co. Ltd. (production license: SCXK (Hu) 2013-0016). Animals were housed in individually ventilated cages, provided with water and standard/high fat chow, and monitored daily for health and clinical signs. All mice were randomly divided into three groups: a normal diet (normal), a high-fat diet (high) and PTFC. In the 7th week, the PTFC group was fed with 50 mg/kg/d PTFC for an additional ten weeks. At the endpoint of 16 weeks, C57 mice were anesthetized with sodium pentobarbital (50mg/kg), sodium pentobarbital was chosen because it is an approved anesthetic method, fast-acting, reliable, and commonly used in animal studies[30]. The dose of it was chosen to be the minimal recommended dose to achieve the anesthetic effect. The animals were euthanized from exsanguination, blood samples were extracted intraocularly, and fresh stool samples were collected and stored at -80°C until further analysis.

### Preparation of PTFC

Pure total flavonoids from citrus were prepared as previously described [16]. PTFC were separated and purified from *Citrus Changshan-huyou* Y.B.Chang by HPD-300 macroporous resin. The main flavonoids were naringin, neohesperidin and naringin. The total flavonoid content was 76.22%.

### Gut microbiota analysis

DNA from faecal samples was extracted using a QIAamp® DNA Stool Mini Kit (Qiagen, Hilden, Germany). The resulting DNA was amplified with specific barcoded bacterial primers targeting the V3-V4 hypervariable region of the 16S rDNA gene using primers: forward primer (5-CCTACGGGNGGCWGCAG-3) and reverse primer (5-GACTACHVGGGTATCTAATCC-3). For each faecal sample, sequencing and bioinformatics were carried out by Genesky Biotechnologies Inc. (Shanghai, China) on the Illumina MiSeq platform to generate 2 × 250 bp paired-end reads. The remaining unique reads were clustered into operational taxonomic units (OTUs) based on the Ribosomal Database Project (RDP) by UPARSE with a 97% similarity cutoff after the raw reads were quality filtered and merged by fastx, Cutadapt, Usearch and FLASH. Mothur was used to perform rarefaction analysis and calculate the community richness index and alpha diversities, including the Shannon and Simpson indexes. Sample tree cluster by Bray-Curtis

distance matrix and an unweighted pair-group method with arithmetic means (UPGMA) and Jaccard principal coordinate analysis (PCoA) based on OTUs were performed using R Project (Vegan package, V3.3.1). Redundancy analysis (RDA) was analysed by Canoco for Windows 4.5 (Microcomputer Power, NY, USA), which was assessed by MCPP with 499 random permutations.

## **Statistical analysis**

Data are presented as the means  $\pm$  standard errors of the mean. The significant differences between and within the different groups were examined using one-way or two-way ANOVAs, followed by Duncan's multiple-range test.  $P < .05$  was considered statistically significant.

## **Abbreviations**

NAFLD: non-alcoholic fatty liver disease;

NAFL: nonalcoholic fatty liver;

NASH: non-alcoholic steatohepatitis;

HCC: hepatocellular carcinoma;

PTFC: Pure total flavonoids from citrus;

PCA: principal component analysis;

PCoA: principal coordinates analysis;

OUT: operational taxonomic unit;

KEGG: Kyoto Encyclopedia of Genes and Genomes;

PICRUSt: Phylogenetic Investigation of Communities by Reconstruction of Unobserved States

## **Declarations**

### **Consent for publication**

Not applicable.

### **Author's contributions**

ZC and SZ designed the study and revised the manuscript. BH and JJ analyzed the data and wrote the manuscript. ZS,DC,SX,MY performed the experiments. All authors read and approved the final manuscript.

## **Authors' Information**

### **Affiliations**

Key Lab of Integrative Chinese and Western Medicine for the Diagnosis and Treatment of Circulatory Diseases of Zhejiang Province, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310006, China

Beihui He, Jianping Jiang, Maoxiang Yan & Zhiyun Chen

Department of Pharmacy, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310006, China

Zheng Shi

Department of Laboratory Medicine, Key Laboratory of Clinical In Vitro Diagnostic Techniques of Zhejiang Province, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, China

Dawei Cui

Department of General Family Medicine, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310006, China

Sumei Xu

Department of Gastroenterology, The First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310006, China.

Shuo Zhang

### **Corresponding authors**

Corresponding to Shuo Zhang or Zhiyun Chen

### **Acknowledgments**

We would like to thank all colleagues in our lab for constructive discussion and technical support.

### **Funding**

The Zhejiang Provincial Natural Science Foundation of China (No. LY17H290007, LYY18H280004) and National Natural Science Foundation of China (No. 81573761)

supported the design of the study. The Fund of State Administration of Traditional Chinese Medicine of Zhejiang Province (Grant No. 2020ZB081), the Fund of Health Commission of Zhejiang Province (Grant

No.2018KY550) supported the collection, analysis, and interpretation of data. The Research Fund of Zhejiang Provincial Key Lab of Diagnosis and Treatment of Circulatory Diseases (Grant No. 2019E10012), and the "Ten thousand plan"-high level talents special support plan of Zhejiang Province (No. ZJWR 0108035) supported and in writing the manuscript.

### **Availability of data and materials**

The dataset analyzed during the current study is available from the corresponding author on reasonable request.

### **Ethics approval and consent to participate**

All experimental procedures were approved by the Animal Ethics Committee of Zhejiang Chinese Medical University and the National Guidelines for Experimental Animal Welfare.

### **Competing Interests**

The authors declare that they have no competing interests.

## **References**


1. G. Porez, J. Prawitt, B. Gross, B. Staels. Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. *J Lipid Res.* 2012;53: 1723–1737. <https://doi.org/10.1194/jlr.R024794>.
2. Sinn DH, Kang D, Chang Y, Ryu S, Cho SJ, Paik SW, et al. Non-alcoholic fatty liver disease and the incidence of myocardial infarction: a cohort study. *J Gastroenterol. Hepatol.* 2019 Sep 11. <https://doi.org/10.1111/jgh.14856>.
3. I. Doycheva, K.D. Watt, N. Alkhoury. Nonalcoholic fatty liver disease in adolescents and young adults: the next frontier in the epidemic, *Hepatology.* 2017; 65:2100–2109. <https://doi.org/10.1002/hep.29068>.
4. H. Zoller, H. Tilg. Nonalcoholic fatty liver disease and hepatocellular carcinoma. *Metabolism.* 2016;65:1151–1160. <https://doi.org/10.1016/j.metabol.2016.01.010>.
5. J. Tong, J.J. Guo. Key molecular pathways in the progression of non-alcoholic steatohepatitis. *Eur Rev Med Pharmacol Sci.* 2019;23:8515–8522. [https://doi.org/10.26355/eurrev\\_201910\\_19165](https://doi.org/10.26355/eurrev_201910_19165).
6. M. Meroni, M. Longo, P. Dongiovanni. The role of probiotics in nonalcoholic fatty liver disease: a new insight into therapeutic strategies. *Nutrients.* 2019;11: E2642. <https://doi.org/10.3390/nu11112642>.
7. L.H.S. Lau, S.H. Wong. Microbiota, obesity and NAFLD. *Adv Exp Med Biol.* 2018; 1061:111–125. [https://doi.org/10.1007/978-981-10-8684-7\\_9](https://doi.org/10.1007/978-981-10-8684-7_9).
8. E. Buzzetti, M. Pinzani, E.A. Tsochatzis. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). *Metabolism.* 2016; 65:1038–1048. <https://doi.org/10.1016/j.metabol.2015.12.012>.

9. A. Takaki, D. Kawai, K. Yamamoto. Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH). *Int J Mol Sci.* 2014;15: 7352–7379.  
<https://doi.org/10.3390/ijms15057352>.
10. A. Albillos, A. Gottardi, M. Rescigno. The gut-liver axis in liver disease: pathophysiological basis for therapy. *J Hepatol.* 2019; pii: S0168-8278(19)30604-X. <https://doi.org/10.1016/j.jhep.2019.10.003>.
11. Y. Ji, Y. Yin, Z. Li, W. Zhang. Gut microbiota-derived components and metabolites in the progression of non-alcoholic fatty liver disease (NAFLD). *Nutrients.* 2019; 11: E1712.  
<https://doi.org/10.3390/nu11081712>.
12. L. Sun, Y. Pang, X. Wang, Q. Wu, H. Liu, B. Liu, et al. Ablation of gut microbiota alleviates obesity-induced hepatic steatosis and glucose intolerance by modulating bile acid metabolism in hamsters. *Acta Pharm Sin B.* 2019;9: 702–710. <https://doi.org/10.1016/j.apsb.2019.02.004>.
13. J. Jiang, L. Yan, Z. Shi, L. Wang, L. Shan, T. Efferth. Hepatoprotective and anti-inflammatory effects of total flavonoids of Qu Zhi Ke (peel of citrus Changshan-Huyou) on non-alcoholic fatty liver disease in rats via modulation of NF-kappa B and MAPKs. *Phytomedicine.* 2019;64:153082.  
<https://doi.org/10.1016/j.phymed.2019.153082>.
14. V. Rodriguez, L. Plavnik, N. Tolosa de Talamoni. Naringin attenuates liver damage in streptozotocin-induced diabetic rats. *Biomed Pharmacother.* 2018; 105: 95–102.  
<https://doi.org/10.1016/j.biopha.2018.05.120>.
15. P.L. Yang, J.P. Jiang, Q.Q. Li, X.M. Wu, Z.Y. Chen, Effects of pure total flavonoids from citrus Changshan-Huyou on blood lipid metabolism in hyperlipidemic rats, *Zhongguo Zhong Yao Za Zhi.* 2017;42:936–943. <https://doi.org/10.19540/j.cnki.cjcm.20170121.008>.
16. Chen T, Wu H, He Y, Pan W, Yan Z, Liao Y, et al. Simultaneously Quantitative Analysis of Naringin and Its Major Human Gut Microbial Metabolites Naringenin and 3-(4'-Hydroxyphenyl) Propanoic Acid via Stable Isotope Deuterium-Labeling Coupled with RRLC-MS/MS Method, *Molecules.* 2019;24(23). pii: E4287. doi: 10.3390/molecules24234287
17. L. Wu, M. Yan, J. Jiang, B. He, W. Hong, Z. Chen. Pure total flavonoids from citrus improve non-alcoholic fatty liver disease by regulating TLR/CCL signaling pathway: a preliminary high-throughput 'omics' study. *Biomed Pharmacother.* 2017;93:316–326.  
<https://doi.org/10.1016/j.biopha.2017.04.128>.
18. Hong W, Li S, Wu L, He B, Jiang J, Chen Z. Prediction of VEGF-C as a Key Target of Pure Total Flavonoids From Citrus Against NAFLD in Mice via Network Pharmacology. *Front Pharmacol.* 2019 Jun 4;10:582. doi: 10.3389/fphar.2019.00582. eCollection 2019.
19. Z.Y. Chen, J.S. Li, J.P. Jiang, M.X. Yan, B.H. He. Effect of pure total flavonoids from citrus on hepatic SIRT1/PGC-1alpha pathway in mice with NASH. *Zhongguo Zhong Yao Za Zhi.* 2014; 39: 100–105.
20. J.S. Li, Z.Y. Chen, J.P. Jiang, B.H. He. Regulation of pure total flavonoids from citrus on TH17/Treg balance in mice with NASH. *Zhongguo Zhong Yao Za Zhi.* 2015; 40: 2644–2648.
21. Y. Wang, H. Zhang, L. Zhu, Y. Xu, N. Liu, X. Sun, et al. Dynamic distribution of gut microbiota in goats at different ages and health states. *Front Microbiol.* 2018; 9:2509.

<https://doi.org/10.3389/fmicb.2018.02509>.


22. J.L. Waters, R.E. Ley. The human gut bacteria Christensenellaceae are widespread, heritable, and associated with health. *BMC Biol.* 2019; 17: 83. <https://doi.org/10.1186/s12915-019-0699-4>.
23. Y. Liu, T. Li, A. Alim, D. Ren, Y. Zhao, X. Yang. Regulatory effects of stachyose on colonic and hepatic inflammation, gut microbiota dysbiosis, and peripheral CD4(+) T cell distribution abnormality in high-fat diet-fed mice. *J Agric Food Chem.* 2019;67:11665–11674. <https://doi.org/10.1021/acs.jafc.9b04731>.
24. A.A. Hibberd, C.C. Yde, M.L. Ziegler, A.H. Honore, M.T. Saarinen, S. Lahtinen, et al. Probiotic or synbiotic alters the gut microbiota and metabolism in a randomised controlled trial of weight management in overweight adults. *Benef Microbes.* 2019;10:121–135. <https://doi.org/10.3920/bm2018.0028>.
25. F. Shen, R.D. Zheng, X.Q. Sun, W.J. Ding, X.Y. Wang, J.G. Fan. Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease, *Hepatobiliary Pancreat. Dis Int.* 2017;16:375–381. [https://doi.org/10.1016/s1499-3872\(17\)60019-5](https://doi.org/10.1016/s1499-3872(17)60019-5).
26. C.C. Chiu, Y.H. Ching, Y.P. Li, J.Y. Liu, Y.T. Huang, Y.W. Huang, et al. Nonalcoholic fatty liver disease is exacerbated in high-fat diet-fed gnotobiotic mice by colonization with the gut microbiota from patients with nonalcoholic steatohepatitis. *Nutrients.* 2017;9:E1220. <https://doi.org/10.3390/nu9111220>.
27. C. Depommier, A. Everard, C. Druart, H. Plovier, M. Van Hul, S. Vieira-Silva, et al. Supplementation with *Akkermansia muciniphila* in overweight and obese human volunteers: a proof-of-concept exploratory study. *Nat Med.* 2019; 25: 1096–1103. <https://doi.org/10.1038/s41591-019-0495-2>.
28. T. Zhang, Q. Li, L. Cheng, H. Buch, F. Zhang, *Akkermansia muciniphila* is a promising probiotic. *Microb Biotechnol.* 2019;12:1109–1125. <https://doi.org/10.1111/1751-7915.13410>.
29. A. Zhu, J. Chen, P. Wu, M. Luo, Y. Zeng, Y. Liu, et al. Cationic polystyrene resolves nonalcoholic steatohepatitis, obesity, and metabolic disorders by promoting eubiosis of gut microbiota and decreasing endotoxemia. *Diabetes.* 2017; 66:2137–2143. <https://doi.org/10.2337/db17-0070>.
30. Loufrani L, Levy BI, Henrion D. Defect in microvascular adaptation to chronic changes in blood flow in mice lacking the gene encoding for dystrophin. *Circ Res.* 2002;91(12):1183-1189.

## Figures




**Figure 1**

Alpha Diversity. (A) Observed (B) Chao1 (C) ACE (D) Rank-abundance distribution curve (E) Samplerarefaction rank curves (F) Sample Shannon curves (G) Species accumulation curve.




**Figure 2**

LfSe Analysis (A)taxon.stat.cladogram (B)taxon.stat.res.Venn diagrams describing the number of operational taxonomic units that are distinct and shared across the groups (C) Venn diagrams.



**Figure 3**

Analysis of the whole intestinal microbiota composition. At the family level, (A) the relative abundance of Christensenellaceae, (B) the relative abundance of Erysipelotrichaceae, (C) the relative abundance of Porphyromonadaceae, and (D) the relative abundance of Streptococcaceae. At the genus level, (E) the relative abundance of Allobaculum (F) and the relative abundance of Eubacterium.



**Figure 4**

HFD-induced alteration of the gut microbiota in NAFLD mice. (A) Relative abundance of the major bacteria at the family level in the three groups. (B) Relative abundance of the major bacteria at the genus level in the three groups. Community composition analysis in the three groups. (C) Normal.family.pieplot, (D) High.family.pieplot, (E) PTFC.family.pieplot, (F) Normal.genus.pieplot, (G) High.genus.pieplot, and (H) PTFC.genus.pieplot. KEGG (I) KEGG\_ANOVA\_diff\_0.05 and (J) group\_different\_analysis KEGG.

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [NC3RsARRIVEGuidelinesChecklistfillable.pdf](#)